IQVIA

USA Patient Registry Software Market Outlook to 2028, Featuring IQVIA, Optum (UnitedHealth Group), Phytel, Dacima Software, FIGmd, Syapse and Pharos Innovations - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 19, 2024
Oncology, Research, Software, University, Infectious Diseases, Education, Hospitals, Health Technology, Genetics, Health Insurance, Data Management, Science, Technology, Clinical Trials, Biotechnology, FDA, Insurance, Health, Professional Services, IOT (Internet of Things), Data Analytics, White House, Federal Government, Practice Management, Managed Care, Other Health, Public Policy, Government, Pharmaceutical, Other Science, Pancreatic disease, Consolidated, Patient, Conditional sentence, Optum, Health information management, Food and Drug Administration, Geography, NPF, RWE, Internet of things, Openclinica, DNA, Policy, Electronic health record, NIH, City, Privacy, CMS, Food, Organization, Prevalence, Federation, Internet, Cancer, Drug development, IQVIA, Evidence-based medicine, RDCRN, Type, Data science, Caregiver, Public health surveillance, Government agency, Registry, EHR, CDC, National Institutes of Health, Bangladesh Technical Education Board, Medicare, Collection, Medical device

The patient registry market in the US involves the collection, management & analysis of data related to patients with specific medical conditions & diseases.

Key Points: 
  • The patient registry market in the US involves the collection, management & analysis of data related to patients with specific medical conditions & diseases.
  • Patient registry software could facilitate data sharing and analysis among these entities, leading to increased adoption
    The patient registry software market in the USA is a part of the broader healthcare information technology sector.
  • Key players in the USA patient registry software market includes IQVIA, Dacima Software, OpenClinica, FIGmd, Dendrite Clinical Systems and various universities conducting medical clinical studies.
  • As technology & data science continue to evolve, the patient registry software market is likely to incorporate more advanced analytics techniques.

Orsini Announcement: Orsini Specialty Pharmacy Welcomes Two Executive Leadership Hires

Retrieved on: 
Thursday, April 4, 2024
Haddock, Growth, CFO, Eisai, Patient, ELK, Pharmacy, University, Senior, Express Scripts, IQVIA, Economics, Management

ELK GROVE VILLAGE, III., April 4, 2024 /PRNewswire/ -- Orsini Specialty Pharmacy is pleased to announce that it has welcomed Victor Haddock as its new Chief Financial Officer and Lynda Parker as Executive Vice President of Trade Relations and Account Management.

Key Points: 
  • ELK GROVE VILLAGE, III., April 4, 2024 /PRNewswire/ -- Orsini Specialty Pharmacy is pleased to announce that it has welcomed Victor Haddock as its new Chief Financial Officer and Lynda Parker as Executive Vice President of Trade Relations and Account Management.
  • Orsini Specialty Pharmacy welcomes Victor Haddock and Lynda Parker to Executive Leadership Team.
  • Haddock has over 25 years of financial leadership experience in the healthcare sector, with a demonstrated ability to lead business strategies, implement change and build successful teams.
  • He most recently served as CFO of Triple-S Management in Puerto Rico, and he has held leadership positions at MagellanRx and Express Scripts.

Patient Registry Software Market Projected to Reach $4.44 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Thursday, April 4, 2024
Oracle Corporation, IBM, Growth, Intelligence, Conditional sentence, USAID, Research, IQVIA, Digital health, Health information exchange, Health, Safety, EHR, Disease, Trial of the century, Digital technology, Collection, Table, Medical device

The healthcare industry is witnessing a transformation by adopting patient registry software, a dynamic tool designed to aggregate, manage, and analyze patient data across various medical specialties.

Key Points: 
  • The healthcare industry is witnessing a transformation by adopting patient registry software, a dynamic tool designed to aggregate, manage, and analyze patient data across various medical specialties.
  • Africa is embracing the potential of patient registry software, driven by a commitment to addressing chronic diseases and enhancing healthcare quality.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Patient Registry Software Market.
  • "Dive into the Patient Registry Software Market Landscape: Explore 191 Pages of Insights, 748 Tables, and 28 Figures"

Patient Registry Software Market Projected to Reach $4.44 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Thursday, April 4, 2024
Oracle Corporation, IBM, Growth, Intelligence, Conditional sentence, USAID, Research, IQVIA, Digital health, Health information exchange, Health, Safety, EHR, Disease, Trial of the century, Digital technology, Collection, Table, Medical device

The healthcare industry is witnessing a transformation by adopting patient registry software, a dynamic tool designed to aggregate, manage, and analyze patient data across various medical specialties.

Key Points: 
  • The healthcare industry is witnessing a transformation by adopting patient registry software, a dynamic tool designed to aggregate, manage, and analyze patient data across various medical specialties.
  • Africa is embracing the potential of patient registry software, driven by a commitment to addressing chronic diseases and enhancing healthcare quality.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Patient Registry Software Market.
  • "Dive into the Patient Registry Software Market Landscape: Explore 191 Pages of Insights, 748 Tables, and 28 Figures"

Healthcare Analytics Market Size to Grow by USD 66.54 billion from 2024 to 2028, Market growth at 24.79% CAGR expected during the forecast period, Technavio

Retrieved on: 
Thursday, March 14, 2024
Komodo, Cloud, Conditional sentence, Informatics, Corp, Component, Health, UnitedHealth Group, Epidemic, IQVIA, Health care, Artificial intelligence, Telehealth, Health information management, USD, Oracle Corporation, Risk, Policy, Cerner, Electronic health record, Information management, SAS Institute, Financial management, Automation, Documentation, Health information exchange, Risk management, Intelligence, Data mining, AI, Veeva Systems, Machine learning, Service, IBM, Mining, Growth, Big data, McKesson Corporation, Health informatics, EHR, Hardware, Retail

The report provides actionable insights and estimates the contribution of all regions to the growth of the global healthcare analytics market.

Key Points: 
  • The report provides actionable insights and estimates the contribution of all regions to the growth of the global healthcare analytics market.
  • The Healthcare Analytics Market is experiencing significant growth driven by advancements in healthcare data analytics, which encompass clinical, predictive, prescriptive, and descriptive analytics.
  • The Healthcare Analytics Market is witnessing substantial growth driven by advancements in healthcare data analytics, encompassing clinical, predictive, prescriptive, and descriptive analytics.
  • Emerging technologies drive market opportunities amidst challenges, positioning the healthcare analytics market for substantial growth and dynamic evolution.

EQS-News: BIO-Europe Spring® 2024 is only a few days away

Retrieved on: 
Wednesday, March 13, 2024
Biotechnology, Merck, Partnering, SVP, Life, ESC, Merck Group, Business development, University, Sustainable business, IQVIA, CSO, Ferrer, Partnership

Munich, Germany – March 7, 2024.

Key Points: 
  • Munich, Germany – March 7, 2024.
  • EBD Group is thrilled to welcome the global biopharma community to Barcelona, Spain, March 18–20.
  • Over 3,700 delegates are looking forward to meeting one-to-one to elevate life science partnerships globally.
  • The session “For a greener globe: Biopharma’s journey to a sustainable future” is scheduled for the afternoon on Monday, March 18.

Supernus Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 27, 2024
Central nervous system, Topiramate, Investigational New Drug, PD, Total, New Drug Application, FDA, Food, Growth, PDUFA, Safety, GAAP, CNS, Depreciation, IQVIA, Patient, AISRS, Attention deficit hyperactivity disorder, DSM-IV codes, ADHD, Phase, MDD, Prescription, MADRS, Pharmaceutical industry

ROCKVILLE, Md., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the fourth quarter and full year of 2023 and associated Company developments.

Key Points: 
  • Fourth quarter 2023 net sales of Qelbree® increased 97% to $46.4 million compared to fourth quarter 2022; Full year 2023 net sales of Qelbree increased 129% to $140.2 million compared to full year 2022.
  • Fourth quarter 2023 net sales of GOCOVRI® increased 10% to $32.0 million compared to fourth quarter 2022; Full year 2023 net sales of GOCOVRI increased 15% to $119.6 million compared to full year 2022.
  • Full year 2023 operating loss (GAAP) was $(5.3) million; Full year 2023 operating earnings (non-GAAP)(2), were $125.1 million.
  • ROCKVILLE, Md., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the fourth quarter and full year of 2023 and associated Company developments.

IQVIA CFO Ron Bruehlman to Speak at Barclays Annual Global Healthcare Conference on March 13, 2024

Retrieved on: 
Wednesday, March 6, 2024
Research, Technology, Security, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Data Management, Science, IQVIA, Barclays, IQV, Webcast, Conference

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Barclays 26th Annual Global Healthcare Conference in Miami on Wednesday, March 13, 2024 at 9:30 a.m.

Key Points: 
  • IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Barclays 26th Annual Global Healthcare Conference in Miami on Wednesday, March 13, 2024 at 9:30 a.m.
  • ET.
  • A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com .
  • A replay of the webcast will be available later that day.

IQVIA CFO Ron Bruehlman to Speak at Citi’s Unplugged Medtech and Life Sciences Access Day on February 29, 2024

Retrieved on: 
Wednesday, February 21, 2024
Technology, Biotechnology, Health, Other Health, Pharmaceutical, Other Science, Other Technology, Research, Medical Devices, Software, Health Technology, Science, Data Management, Security, IQVIA, IQV, Webcast

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at Citi’s 2024 Unplugged Medtech and Life Sciences Access Day in New York on Thursday, February 29, 2024 at 9:30 a.m.

Key Points: 
  • IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at Citi’s 2024 Unplugged Medtech and Life Sciences Access Day in New York on Thursday, February 29, 2024 at 9:30 a.m.
  • ET.
  • A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com .
  • A replay of the webcast will be available later that day.

PanOxyl® Named #1 Dermatologist-Recommended Benzoyl Peroxide Brand

Retrieved on: 
Thursday, February 22, 2024
Acne, EVP, Benzoyl peroxide, Skin, Walmart, IQVIA, Ulta, CVS, Dermatology, Face, Target, Cosmetics

JOHNSON CITY, Tenn., Feb. 22, 2024 /PRNewswire/ -- Crown Laboratories, Inc., a leader in innovative skincare solutions, is thrilled to announce that its best-selling acne wash, PanOxyl®, has been named the #1 dermatologist recommended Benzoyl Peroxide brand.* A portfolio comprised of products that cleanse, manage, or moisturize acne-prone skin, PanOxyl is a go-to solution for millions of consumers across the country.

Key Points: 
  • PanOxyl's #1 dermatologist-recommended status is validated by a recent IQVIA ProVoice survey recording dermatologists' recommendations of Benzoyl Peroxide.
  • The survey concluded that PanOxyl was the most recommended over-the-counter brand – 53.8% of the time and twice as much as any other brand.
  • There is no doubt that as the #1 dermatologist-recommended Benzoyl Peroxide brand, PanOxyl is a powerhouse solution that acne suffers can rely on."
  • Visit www.PanOxyl.com to learn more about the #1 Benzoyl Peroxide brand and other products from the brand's portfolio.